MVZ Nordoberpfalz GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At MVZ Nordoberpfalz GmbH, the cardiovascular research portfolio focuses on preventing major heart and vascular events in people with established disease or elevated risk. Studies are exploring whether new lipid-targeting therapies can better reduce myocardial infarction, stroke, and other serious outcomes, while also assessing long-term safety and tolerability.
- Prevention of major cardiovascular events in people with atherosclerotic cardiovascular disease
- Research on lowering lipoprotein(a) to reduce heart attack and stroke risk
- Evaluation of long-term safety for newer cardiovascular therapies
This work aims to improve treatment options for patients at risk of first or recurrent cardiovascular events and to support more effective risk reduction in routine care.
Neoplasms
The oncology program at the Department of Oncology and Hematology covers a broad range of cancer research, including bladder, breast, prostate, colorectal, gastric, pancreatic, and blood cancers. The trials are mainly designed to test new treatment combinations, improve disease control, and refine approaches that may preserve organs or reduce the need for extensive surgery.
- Studies in breast cancer and prostate cancer evaluating newer treatment strategies
- Research in bladder cancer, rectal cancer, and colon cancer aimed at improving outcomes and organ preservation
- Trials in multiple myeloma, chronic lymphocytic leukemia, and small lymphocytic lymphoma focused on better disease control
- Studies in pancreatic cancer and gastric or esophagogastric cancer testing new therapeutic approaches
The research landscape here reflects a strong emphasis on precision oncology, combining treatment effectiveness with efforts to improve quality of life and clinical outcomes across several major malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Novartis Pharma AG1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ Nordoberpfalz GmbH
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Calcium Folinate Pentahydrate | 3 | Unknown | 2018-09-03 | 2020-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.